Literature DB >> 3754878

Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection.

B R Murphy, B S Graham, G A Prince, E E Walsh, R M Chanock, D T Karzon, P F Wright.   

Abstract

An enzyme-linked immunosorbent assay (ELISA) with immunoaffinity-purified fusion (F) or attachment (G) glycoprotein was used to measure the serum and secretory immune responses of 18 infants and children, 4 to 21 months of age, who underwent primary infection with respiratory syncytial virus (RSV). Most of the 10 older individuals (9 to 21 months of age) developed moderate levels of serum and nasal-wash immunoglobin A (IgA) and IgG F and G antibodies. These individuals developed a moderate level of serum or nasal-wash antibodies that neutralized virus infectivity. One of the eight younger individuals (4 to 8 months of age) failed to develop an F antibody response, while three failed to develop a G antibody response. The most notable difference in the responses of the two age groups involved the titer in convalescent sera of G, F, and neutralizing antibodies which were 8- to 10-fold lower in younger individuals. Most of the younger infants failed to develop a rise in serum or nasal-wash neutralizing antibody. It is possible that the presence of maternally derived antibody in the younger infants suppressed the immune response to RSV infection, and that this accounted, in part, for the low level of postinfection antibody titer in this group. This low level and the irregular response of the infants less than 8 months of age may contribute to the severity of their initial infection and may also be responsible, in part, for their failure to develop effective resistance to subsequent reinfection by RSV.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3754878      PMCID: PMC268782          DOI: 10.1128/jcm.23.6.1009-1014.1986

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  35 in total

1.  Respiratory syncytial virus. I. Virus recovery and other observations during 1960 outbreak of bronchiolitis, pneumonia, and minor respiratory diseases in children.

Authors:  R M CHANOCK; H W KIM; A J VARGOSKO; A DELEVA; K M JOHNSON; C CUMMING; R H PARROTT
Journal:  JAMA       Date:  1961-05-27       Impact factor: 56.272

2.  Clinically useful method for the isolation of respiratory syncytial virus.

Authors:  C B Hall; R G Douglas
Journal:  J Infect Dis       Date:  1975-01       Impact factor: 5.226

3.  Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex.

Authors:  R H Parrott; H W Kim; J O Arrobio; D S Hodes; B R Murphy; C D Brandt; E Camargo; R M Chanock
Journal:  Am J Epidemiol       Date:  1973-10       Impact factor: 4.897

4.  Experimental respiratory syncytial virus infection of adults. Possible mechanisms of resistance to infection and illness.

Authors:  J Mills; J E Van Kirk; P F Wright; R M Chanock
Journal:  J Immunol       Date:  1971-07       Impact factor: 5.422

5.  Cell-free and cell-bound antibody in nasal secretions from infants with respiratory syncytial virus infection.

Authors:  K McIntosh; J McQuillin; P S Gardner
Journal:  Infect Immun       Date:  1979-02       Impact factor: 3.441

6.  Hemagglutinin-specific enzyme-linked immunosorbent assay for antibodies to influenza A and B viruses.

Authors:  B R Murphy; M A Phelan; D L Nelson; R Yarchoan; E L Tierney; D W Alling; R M Chanock
Journal:  J Clin Microbiol       Date:  1981-03       Impact factor: 5.948

7.  The immunologic response to infection with respiratory syncytial virus in infants.

Authors:  K McIntosh; H B Masters; I Orr; R K Chao; R M Barkin
Journal:  J Infect Dis       Date:  1978-07       Impact factor: 5.226

8.  Enzyme-linked immunosorbent assay for measurement of serological response to respiratory syncytial virus infection.

Authors:  L S Richardson; R H Yolken; R B Belshe; E Camargo; H W Kim; R M Chanock
Journal:  Infect Immun       Date:  1978-06       Impact factor: 3.441

9.  Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children.

Authors:  F W Henderson; A M Collier; W A Clyde; F W Denny
Journal:  N Engl J Med       Date:  1979-03-08       Impact factor: 91.245

10.  The antibody response to primary and secondary infection with respiratory syncytial virus: kinetics of class-specific responses.

Authors:  R C Welliver; T N Kaul; T I Putnam; M Sun; K Riddlesberger; P L Ogra
Journal:  J Pediatr       Date:  1980-05       Impact factor: 4.406

View more
  52 in total

Review 1.  The respiratory syncitial virus and its role in acute bronchiolitis.

Authors:  M L Everard; A D Milner
Journal:  Eur J Pediatr       Date:  1992-09       Impact factor: 3.183

2.  Oral retinyl palmitate or retinoic acid corrects mucosal IgA responses toward an intranasal influenza virus vaccine in vitamin A deficient mice.

Authors:  S L Surman; B G Jones; R E Sealy; R Rudraraju; J L Hurwitz
Journal:  Vaccine       Date:  2014-03-21       Impact factor: 3.641

3.  Antibody response to respiratory syncytial virus infection in children <18 months old.

Authors:  Susanna Esposito; Elisa Scarselli; Mara Lelii; Alessia Scala; Alessandra Vitelli; Stefania Capone; Marco Fornili; Elia Biganzoli; Annalisa Orenti; Alfredo Nicosia; Riccardo Cortese; Nicola Principi
Journal:  Hum Vaccin Immunother       Date:  2016-02-22       Impact factor: 3.452

Review 4.  Why do viruses make infants wheeze?

Authors:  I M Balfour-Lynn
Journal:  Arch Dis Child       Date:  1996-03       Impact factor: 3.791

Review 5.  Immunity to human and bovine respiratory syncytial virus.

Authors:  T G Kimman; F Westenbrink
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

Review 6.  Vaccine Design Informed by Virus-Induced Immunity.

Authors:  Rhiannon R Penkert; Jane S Hankins; Neal S Young; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2020-05-05       Impact factor: 2.257

Review 7.  Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections.

Authors:  V G Hemming; G A Prince; J R Groothuis; G R Siber
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132

8.  Inability to evoke a long-lasting protective immune response to respiratory syncytial virus infection in mice correlates with ineffective nasal antibody responses.

Authors:  Richard Singleton; Nathalie Etchart; Sam Hou; Lisa Hyland
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

9.  Primary human mDC1, mDC2, and pDC dendritic cells are differentially infected and activated by respiratory syncytial virus.

Authors:  Teresa R Johnson; Christina N Johnson; Kizzmekia S Corbett; Gretchen C Edwards; Barney S Graham
Journal:  PLoS One       Date:  2011-01-28       Impact factor: 3.240

10.  Serodiagnosis of respiratory syncytial virus (RSV) infection in children as measured by detection of RSV-specific immunoglobulins G, M, and A with enzyme-linked immunosorbent assay.

Authors:  M J Meddens; P Herbrink; J Lindeman; W C van Dijk
Journal:  J Clin Microbiol       Date:  1990-01       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.